In short
Podcast Notes: CNBC's "Fast Money" Episode - 2025 IPO Predictions, Tariff Risks (11/26/24)
Episode Overview
- Host: Melissa Lee
- Guests: Tim Seymour, Dan Nathan, Guy Adami, Katie Stockton
- Topics:
- Trump's new tariff threats on Mexico, Canada, and China
- Amgen's disappointing trial results for its obesity drug
- VIX movements and market volatility
- Prospects for the 2025 IPO market driven by small caps
---
Key Segments
- Trump's Tariff Threats
- Context: President-elect Trump is set to impose significant tariffs (25%) on products from Mexico and Canada and an additional 10% on Chinese goods on his first day in office.
- Discussion Points:
- Trade Strategy: Analysts question whether this is tough rhetoric or a serious negotiation tactic. The challenges in enforcing these tariffs are highlighted.
- Market Reaction: ETFs tied to Mexico and Canada saw declines, while the U.S. dollar strengthened against these currencies.
- Comments from Eamon Javers:
- The tariffs set an "almost unattainable" compliance standard for foreign countries which may hinder effective negotiations.
- Mexico's president hinted at retaliatory tariffs, raising concerns about a potential trade war.
- Amgen's Obesity Drug Trial Results
- Overview: Amgen's experimental GLP-1 obesity drug showed a 20% weight loss over 52 weeks, but this fell short of market expectations (25%).
- Market Impact:
- Stock dropped significantly due to concerns about side effects (11% dropout rate attributed to adverse events).
- Analysts remain cautious yet optimistic about future phases of the trial.
- The Biden administration's proposal to cover obesity medications could expand access for millions.
- Market Volatility and VIX Analysis
- Current VIX Situation: The VIX is trading below $14, indicating a period of low volatility.
- Katie Stockton:
- Indicates potential for a market correction if VIX support levels are breached.
- Suggests preparing for market opportunities in early 2025.
- Small Caps and the 2025 IPO Market
- Market Insights:
- The Russell 2000 is up nearly 10% in the last month, approaching record highs.
- This resurgence could stimulate IPO activity as small caps often drive the new issue market.
- Seth Rubin's Predictions:
- Anticipates a pickup in tech and healthcare IPOs, especially with a backlog of high-quality companies waiting to go public.
- Emphasizes the importance of conservative growth projections from companies going public.
---
Key Takeaways
- Tariff Strategy: Trump's aggressive tariff threats may serve as negotiation leverage rather than immediate policy, with the potential for significant market repercussions.
- Pharmaceutical Market: Despite Amgen's setbacks, the obesity drug market holds potential with future trials and possible government support.
- Market Conditions: Analysts believe the current low volatility phase could shift, requiring investors to be strategic in their approach.
- IPO Outlook: The positive movement in small caps may lead to a revitalized IPO market, particularly in tech and healthcare sectors, with a focus on sustainable growth metrics.
---
Conclusion This episode of "Fast Money" offers a comprehensive look at current market dynamics influenced by political actions, corporate trials, and investor sentiment. Key traders provide insights that could guide investment strategies leading into 2025 amidst various economic indicators and geopolitical factors.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:02Live from the Nasdaq market date on a day when the Dow and S &P close at fresh all time highs. This is Fast Money. Here's what's on tap tonight. Trump's new tariff threat. The president-elect set to levy massive new tariffs on Mexico, Canada, and China on day one of his new administration. Is this part of his deal-making strategy or a true attack on our biggest trade partners? Plus, obesity bummer Amgen, the Dow's worst performer after disappointing results for its experimental GLP-1 drug. We'll talk to one analyst who still thinks this stock is a buy. And later, a technical take on the move lower in the VIX.
0:34Inside Best Buy is bad day and quarter. and why the recent surge in small caps could help fuel an IPO boom in 2025. I'm Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Dan Nathan, Guy Adami, and Katie Stockton of Fairleaf Strategies. And we start off with Trump's latest tariff threats. The president-elect warning he will place a 25 percent tariff on all products coming from Mexico and Canada on his first day in office until drugs and illegal immigrants stop moving into the country. He also plans to raise China tariffs an additional 10 percent. Sox were sluggish out of the gate, but rebounded by the end of the day.
1:08The S &P 500 and Dow closing at fresh record highs. But some areas of the market were hit by Trump's threat. The ETFs of Mexico and Canada, for instance, falling today. The Mexico and Canada ETF sinking 1 to 3 percent. The dollar also climbing against the Mexican peso and Canadian dollar. CNBC's Eamon Javers is here to take us inside the details of the story. Is this all just tough talk, Eamon? It is tough talk. And the question is how much substance is behind it. The president-elect's flurry of social media posts Monday night are raising the question of what he's up to here, because the bar he's setting for compliance by foreign countries is almost unattainable to stop all illegal immigration, all fentanyl into the United States.
1:44So what is this really about? Well, Trump took to social media to complain about that human migration and drug trafficking, suggesting that he'll impose tariffs on Mexico, Canada and China until the flow of fentanyl in particular has stopped. In a Truth Social post, Trump wrote that drugs are pouring into the country, mostly through Mexico, and until they stop, he will charge China an additional 10 percent tariff. Now, the Chinese embassy in Washington responded with a statement saying no one will win a trade war or a tariff war. The idea of China knowingly allowing fentanyl precursors to flow into the United States runs completely counter to facts and reality.
2:21So what may be going on here is an attempt by Trump to speed up a renegotiation of the U.S.-Mexico trade agreement that he signed back in 2020. That deals up for renegotiation in 26. But Trump may be calculating here that he can bring all sides to the table earlier using the leverage of these social media posts about the tariffs, Melissa. One question here is his strategy is sort of a seesaw, right? If in theory it works and you put the tariffs in and fentanyl trade declines, then you have to pull the tariffs off in response to that. So what Trump really wants, I think, is both tariffs and an end to the fentanyl trade.
2:59And he set up a seesaw dynamic where he doesn't get both in theory. We'll see whether this is reality when he takes office or whether this is an attempt to bring all those folks to the table. And Eamon, you outlined the response from the Chinese embassy, but Mexico's president also responded saying that they will basically open a tit for tat. So Trump levies tariffs and they will also impose tariffs of their own. So it seems like this time around, Trump 2.0, some of these countries are willing to actually stand up to these tariffs. Yeah, that's the problem with the trade war, Melissa, is that the other side gets to fire back.
3:31You know, and this is not just a unilateral decision by the president of the United States. This is a question of whether you want to get into a cycle of these tit-for-tat responses and see how far that takes you. And who wins in that scenario is an interesting question. That's, you know, the Chinese statement says nobody wins in a trade war. The president-elect clearly believes that the United States can win and he will win in a trade war. And that's why he's doing this. Eamon, thank you. Eamon Jivers in Washington for us. Should we be worried? Should we trade off the threat of tariffs, Guy? I think you can trade the bond market off it.
4:07Clearly, the equity market is not worried, but I think the bond market should. Next year, we're going to have$1.5 trillion just in interest to service the debt. Think about that. And then that's on top of all the issuances that have to be done in 2025. Now, this might be the right course of action without question. But again, I think it's inflationary. I don't think the bond market at 4.3 % to 10 years of pricing it in. At 4.5 % two weeks ago, I don't think it was pricing it in. And so for me, the way to play this is through the bond market thinking yields will go higher. You hear about it on the headline pushing back against Trump and against the U.S., who is the biggest economy in the world.
4:41Mexico right now recently overtook China as being the largest source of imports into this country, a little over 15 percent. It was only 12 percent a few years ago. So Mexico has been picking up steam. And the question is, if you're Mexico, do you really want to take the U.S. on? I don't think so. Having said that, you can't look like you're just going to fall down. And I think if you look at certain sectors that were most hit today, the auto sector specifically, it's argued that, you know, some 97 billion. I'm quoting actually Emanuel Rosner at Wolf, who said 97 billion worth of auto parts are shipped to the U.S.
5:12from other countries, but specifically through Mexico and Canada. So there are places that are particularly well, you know, I think hurt more than others. Jim, which had also been riding very high coming into today. I think that partly explains some of that move. But look, I think we've we've speculated now for weeks. We had a day yesterday. This is why this is fascinating stuff and why this is a trading show, because yesterday we had Scott Bessent, new Treasury at least secretary, proposed is someone that says, hey, look, I'm going to do my best. Or at least it was thought he's the moderate voice in the room and the room that's going to be worried about deficits and probably not push as hard on tariffs.
5:49We'll see. I think it's a lot of bluster. I mean, we have four years to kind of see what happened in the first administration. We've heard lots of tweets over the last four years. And you think about it. I mean, he has to kind of try to follow through with some of the promises he made on the campaign trail. I go back to September when he threatened John Deere, a great American company, with 200 percent tariffs for equipment coming in from Mexico. Well, at the end of the day, five percent of their sales come from Mexico. Right. Three quarters of their production happens here in the U.S. So I guess at the end of the day, a lot of U.S.
6:19companies are probably not going to make any big moves as it relates to manufacturing based on these threats. Because I think that if you look at all the nominations, I think a lot of folks, to Tim's point, look at a guy like Besson and they say these folks are going to have some pretty decent influence, not too different than Gary Cohn in the first administration. So I just don't think you're going to see too many big decisions by U.S. manufacturers based on these threats right now. And overall, the markets are acting fairly well, taking all this in stride, Katie. Yeah, I would agree. I mean, we have very positive momentum, of course, behind the major indices, and it shows optimism around the administration.
6:53So we've got to stay with the momentum, really. The relative performance U.S. versus international, especially Mexico, maybe to a lesser degree Canada, is still very positive. And we want to stay on the right side of that trade, at least as long as it's working and it's still working. Yeah, and I guess that's a question here, Guy. You can hear all these headlines that may sound inflationary, bad for the consumer, all of these negative potential impacts on the economy. And yet we have a market that wants to go higher into year end. No question. So do you embrace that? I don't embrace it, but it's not about me.
7:25I mean, the market is embracing it. The money flows are embracing it clearly. And there's an enthusiasm, I think, when people believe it's going to happen in 2025. The math suggests otherwise, if you start looking at things again, valuations are not timing tools, but the market's gotten itself extraordinarily expensive in a short period of time. We talk about Warren Buffett and his$325 billion that he's raised. He's clearly looking at something. His indicator is north of 200 percent at 23 times next year's numbers. The market is historically rich. I mean, there's a lot of things to be concerned about.
7:55And we can say that it's all bluster, and that might be true. But you know what? President-elect Trump hears that as well. So enough people have said that this is just a negotiating tool, that maybe it's not a negotiating tool. Maybe there is a line in the sand. And again, I don't think at 4.3 % in the 10-year we're pricing that in. And I think there are sectors that really benefit from this. I mean, we've talked about some that don't. And it also comes at a time when the market, as we've said, is broadening into a place where the move in the consumer and the retail stuff over the last three or four sessions has been extraordinary.
8:22And I don't know that it necessarily tells you exactly the health of the consumer, but it does tell you a dynamic. And this is on a day when we got Fed minutes that kind of look back at their last meeting. And ultimately, the mindset is that the Fed really doesn't know where neutral is supposed to be. We have liquidity at all-time highs, in my view. In other words, we've been coming out of a tightening period, and seemingly we're still restrictive. Yet, look at where credit spreads are. Look at where the equity markets are. Look where banks are, I think, starting to throw money around. So get back to stocks, and I like it.
8:51I mean, I like the fact that semis have underperformed, and the stock market's going to all-time highs. I think it's very bullish, and I think there actually is going to be funding coming from the MAG-7. It has been coming from the MAG-7 clearly into this broadening, and I think it continues. It seems pretty obvious that the economy is in good shape. I think that's something that a lot of folks kind of believed, you know, for better part of this year. We had GDP prints that were 2.8 percent. I think expectations are now 3 percent. You haven't seen unemployment go up meaningfully over the last, let's call it, I don't know, Guy, you're tracking this, like in the last few months.
9:24I mean, we haven't seen that sort of thing. And so the markets are kind of pricing that in. So I guess the question is, you just mentioned banks, Tim. You know, the banks in particular are pricing in a rip-roaring economy next year. Right. And so at some point, the rubber's got to hit the road a little bit. S &P is up 4 % since the election. I don't think that is some overwhelming sort of vindication of the policies and that sort of thing. And the only thing I'll just say is you're going to have to prioritize all of these threats. There's been a lot of them over the last year. And I don't think that they thought that they're going to have to deal with them all so quickly.
9:55But at the end of the day, the financial ones at least are in the best hands for right now. And I think you're not going to see something come apart. I just don't think we're going to see these tariffs on day one. All right. For more, let's bring in David Wu of David Wu Unbound. He formerly oversaw emerging markets fixed income strategy at Bank of America. David, great to have you with us. Thanks for joining us. Thanks for having me. What's your take about the latest talk about tariffs? And, you know, we have the benefit of having learned what the impact of tariffs could be from the first Trump administration.
10:24So what are your conclusions? I think the most important takeaway from the announcement last night is the fact that China was only hit with a 10 percent tariff versus 25 percent for both Canada and Mexico, which is actually very surprising if you think about this. But then again, if you think about it, it's not that surprising because guess what? The biggest basically tariff, whatever you call it, or monger, Lighthizer, has not yet landed a job in the White House. He should have been the first appointment and yet he has nowhere to be seen. In my view, what this tells me is something obvious, which is very likely Trump has already begun the engagement with the Chinese.
11:02I bet you informal talks are already progressing. Let's think about this. The second most important person in the Trump administration is going to be Elon Musk. Elon Musk has this biggest factory in the world in China. He's building the second biggest factory in the world in China. China is the second largest market for Tesla. So from that point of view, I don't think Elon Musk wants to see a blowout between the U.S. and China. On top of that, given the massive escalation in the Ukraine war, given what Biden is doing to provoke Putin to declare World War III, Trump probably has to now reach out to Xi Jinping, probably who's the only person who's got some leverage over Putin to basically help Trump to bring him across the line.
11:40So I would argue everything being said, I think actually what the announcement yesterday has nothing to do with tariff, has nothing to do with anything. In fact, probably just means that the administration is making a lot more faster progress than you might imagine when it comes to doing a deal with China. So you think there's actually a floor to how bad the relationship with China could get then, which would be sort of counter consensus at this point, because, you know, people on Wall Street are thinking the worst. I mean, if you're talking the big number, 60 percent tariffs, and I know 10 percent is the opening salvo.
12:12But if you're thinking ultimately it's 60, then that could be terrible. Right. So if you're saying that there's a floor because Elon Musk is going to. Exactly. Let's let's remind your viewers some numbers. In 2018, when Trump declared trade war on China, China accounted for 23 percent of total U.S. imports. Today, China only accounts for 13 percent of U.S. imports. In other words, even with 60 percent tariff, you're not going to hurt China that much. You're not going to raise too much revenue and you're not probably not even going to balance the U.S. trade deficit. And I guarantee you what Scott Besson, who is telling Trump, is that, you know what, you can hit China with 60 percent tariff, but long term interest rates are going to go up so much, it's going to make it counterproductive.
12:55You're going to raise less money by hitting China with tariff than you're going to lose by paying out more interest payment, which is now$1.1 trillion. So I think from that point of view, to me, what Trump is after is not the tariff. Trump needs the Chinese to create jobs in the U.S. I think there's a much more obvious deal that they're talking about on the table, which is lifting restriction on foreign investment for the Chinese in the U.S. to allow the likes of BYD to basically come into the U.S., create jobs, build factories and make cars and sell to the Americans, which is what the Americans did for the Japanese 40 years ago, the Koreans 20 years ago and the Germans 10 years ago.
13:33You think Trump really can—I mean, he gives a damn about whether it's the Japanese or the Chinese car, whatever. For Trump, it's only us versus them, and them is the same. So I think as long as the Chinese are willing to build cars in the U.S., I think that will be the win-win. Going back, though, to Elon Musk being the second most important person in the administration, allowing BYD into the country and NIO and all the other Chinese EV makers, for that matter, in, that could really hurt Tesla. So how does that happen in your scenario of Musk being very important? Let's just think about this. Musk has recently said he doesn't want to build a cheap, basically, EV car anymore.
14:12The Model 3 has sort of abandoned the idea because I think he's bracing for this idea of what I'm proposing. In fact, from that point of view, Elon Musk can basically stay competitive at the high end, focus on autonomous driving, which is something the Chinese are not going to be able to actually enter because the whole ban on connectivity. So from that point of view, you know what? You know, BYD is going to probably hurt Toyota, Honda, Hyundai, and so on and so forth. American car manufacturers anyway, not really that big an EV. They basically sell trucks for a living. So from that point of view, let the Chinese take market share from the Japanese, the Koreans, and everybody else.
14:47To me, it's not obvious that Elon Musk is going to be a big loser here. He could actually end up being a big winner. Remember, Elon Musk has already said on a number of occasions, His factory in China is the most productive automobile factory in the world, and he says that they produce the best, highest quality Teslas. That is much more important to Elon Musk in terms of his basically aim to become a global player. David, great to speak with you. Thanks for your time. You're welcome. David Wu. David Wu Unbound. That's a perfect name. Unbound, right? I mean, literally. Love his energy. He's been at Bank of America for decades.
15:23Nice. Yeah, for a long, long time. A lot of interesting, provocative. I don't get the Tesla thing. I mean, this goes back to January. Elon Musk said if their trade barrier is not put up on Chinese EVs, he said this on his conference call, it's going to demolish the EV industry globally. And, you know, when you think about he just said that, you know, like he's going to focus this is Elon on the high end. Model S and Model X are a small percentage of their production right now. They are very focused on this kind of 40 ,000 range car. If BYD comes in here, the average BYD car, I think at a much bigger range, it's like$25 ,000.
15:58You know what I mean? So I think there's no way to spin any of this. We just talked last night about these EV credits. It seems like Trump is on a different page than Elon Musk about a lot of this. So it's going to be very interesting to see how this shakes out. The whole idea, though, that there's going to be some sort of deal and what Trump really wants is the Chinese to come and make jobs for Americans. I mean, that's sort of a very interesting. This is at a time, of course, when China's economy is on its knees. I mean, they have to be a little bit more pragmatic about how they engage with the Trump administration versus the first administration.
16:30That's what I was going to say. I mean, David Wu, who I loved a lot of things he said, because he refers to a pragmatism that's going to take over in this administration. And that's got best and Donald Trump. I mean, that there's a pragmatism to understanding where tariffs don't work. Look, we saw this for the U.S. steel industry and Trump 1.0. It's also very important for U.S. companies that China's economy does better. It doesn't mean we're necessarily going to worry about stimulating China's economy. But at the end of the day, for the markets, if you look at a lot of the consumer discretionary and a lot of the things that have been beaten up on China weakness, there's a huge rally in a lot of those names.
17:01Also, dollar strength, pragmatism, if that takes over, nobody wants a strong dollar. It's great to be pragmatic, but the numbers don't lie. And you don't start with a clean slate when you walk in an office on January 20th, whatever day it is. You walk in with what you've basically inherited. And that is an extraordinary balance sheet in terms of the Fed. and interest rates that I think are going to continue to go higher. He mentioned$1.1 trillion in interest payments. That's this year, accelerating$1.5 trillion next year. I mean, you have to address that at some point. Tariffs don't do that. All right, now to the volatility trade.
17:30The VIX today trading below$14, dropping nearly 40 % just this month. And Katie thinks this chart is up, hanging around key support levels at this point. What are you looking at? Yeah, we definitely have to keep a close eye on it. We believe, and I know Guy agrees, that we've been in this high volatility regime since July, thereabouts per the VIX. And the VIX can be seen as a gauge of market sentiment when it's relatively low, it's considered more complacent, and that is a market risk. So we're right at the support level for the VIX, which has been somewhat range-bound as part of this high volatility cycle.
18:02And we feel that as long as this support level holds, that there still is that risk of a corrective phase, something that maybe we don't sell ahead of, but rather get some sort of dry powder to put to work in January, in February to take advantage of that. So we're really watching this very closely. It's around 14 and a half for the VIX. And if we were to see a breakdown, we would require two weekly closes below that level to confirm a breakdown. Then guess what? It looks like we're probably moving back into a lower volatility cycle, which is more market positive. And the next floor for the VIX is back near 11.
18:39So it's really a critical level for the VIX and really also the broader market, just given the negative correlation. Something resonates. So Katie was here in June, July, and she said that we're about to enter a period of heightened volatility. And it typically lasts nine to 12 months-ish. If I'm putting words in your mouth, I'm sorry. But by August 5th, we saw what happened to the volatility index. And I think a lot of people think that was it. I think that was sort of a precursor, not to suggest we're going back there. But I think there's going to be another round of volatility. These levels are critical.
19:07I think it's going to hold. Coming up, a lot of after hours action to bring you a lot. Here's Adele, CrowdStrike, HP, Autodesk, and Workday all on the move after reporting the details and numbers out of those quarters straight ahead. And Wells Fargo still operating under an asset cap put in place after their fake account scandal. But could the growth restraints be on the way out? The hurdles they still need to clear? What it could mean for the bank's next move. Don't go anywhere. More Fast Money in two.
19:41Welcome back to Fast Money, a pair of tech earnings movers after hours crowd strike lower despite beating top and bottom line estimates. We'll start off with Dell shares tumbling on a mixed report. That conference call is underway. Christina Parts and Elvis has got the details. Hey, Christina. Hi, Melissa. Well, investments in AI did help Dell's infrastructure group, but it just wasn't enough right now to offset any weakness in their more traditional businesses. As the COO saying on the call right now, the PC refresh continues to move out. Quote, we know it's there, but the triggers have been slower to move.
20:10And that delay, along with supply issues with NVIDIA's Blackwell chips, forced Dell management to lower their Q4 revenue guidance to a range between$24 billion and$25 billion. That's lower than estimates. And while you actually saw the stock go from about 5 % negative to about down 10 % in after hours trading, management says they did hit record AI server orders demand in Q3, and their pipeline grew more than 50 percent. But, quote, this business, and this was from the call right now, this business will not be linear, especially as customers navigate an underlying silicone roadmap that is changing.
20:42Regardless, we are winning deals at a price premium to our competition. So definitely a more sober take on AI right now. All right, Christina, thank you. Christina Parts Nevelis, why do we think that NVIDIA gets the pass when it comes to Blackwell delays, but Dell does not get the pass. Because they keep coming out and saying there's insane demand for it. And again, so does NVIDIA. I know, but no, that's what I said. So I don't hear insane demand from their customers for the high end, you know what I mean, the next generation. So there are a couple of things going on here. I think that was the takeaway with NVIDIA's beat and raise last week is that the beat and raises are getting less and less.
21:20And then you keep hearing more about the transition to this higher end. So, you know, I mean, like Dell is a great example of a company that keeps talking about AI demand, but they keep saying the rest of their business is weak, which is not too different what we heard from ASML. So it sounds like the PC business is weak right now, and you're going to have lung-free AI demand. That's what they said. But is that a reason to sell Dell? I mean, I kind of feel like if you're going to let any business be weak, you want that one to be weak. I mean, that's the lower-margin business. That's the old-school business.
21:49The ISG business, so the infrastructure group, is the one that has gotten a lot of excitement around enterprise and, again, multipurpose data servers. And I think that's the story. It comes back to this. I mean, first of all, it's been a roller coaster ride. If you've been playing Dell, Karen's been doing a great job. First of all, you went 90 % up from February to June. You went down 90 % from June to August 5th or that low, and you're up 60%. It trades at about 15 times forward. It's not expensive with a pretty sexy growth business, and it's growing around 10 % a year. So I think you can own it here, even though this isn't the kind of a name that I would like to be chasing.
Read the full transcript
22:25But, you know, I feel like you are. Do you like the chart, Katie? You know, with a 10 percent downdraft, it basically comes back into its rising 50-day moving average. So I feel like that's maybe opportunity for it. The long-term momentum is positive there. Let's get to CrowdStrike earnings now. That stock is lower following its latest results. Kate Rooney's got the latest on that. Kate. Hey, Melissa. So despite that global tech outage this summer, it was a pretty strong beat for CrowdStrike, at least in Q3. The cybersecurity company raised its full-year guidance as well. Revenue for the quarter topping a billion dollars.
22:54That grew 29 percent or so year over year. It did see some strengths in subscription revenue and then profitability with 19 percent operating margins for that quarter. Q4 EPS, though, the guidance at the midpoint of that range was light. And then same with its revenue forecast. That appears to be weighing on the stock after hours. The global tech outage was the elephant in the room going into this report. Street had expected lower growth because of some of the potential delays in renewing contracts. Total ARR outperformed atopped expectations at$4.02 billion. 153 million of that was net new ARR, which some analysts are excited about.
23:31CEO George Kurtz on the call that's going on right now said they were tested, as he put it, after the outage and responded with speed, care and resolve. He called out CrowdStrike's performance in its first full quarter since that incident and 97 percent net retention rate. He said it was down less than half a percentage point. also says through all that, they remain laser focused as he put it on Innovation Mill. Kate, is there any evidence that they had a discount in order to hold on to those contracts where the contracts already signed and so therefore the retention rate stands at full margin?
24:03That was one of the big questions heading into the print. So far on the call, we haven't gotten any indication that this was a result of discounts and saying, hey, stick with us because we're going to lower costs. We'll keep an eye out for that. And that was one of the expectations, but it seems like most of the metrics outperformed AR as well. So it didn't bite into results as the way you would expect if they were giving massive discounts. So no evidence of that at this point, Mel. All right. Kate, thanks. Kate Rooney. Guy, what's the trade? All-time high from 400 to 200 in a month over the summer.
24:33We know that. It basically got the entire thing back. Now, they beat by 12 cents. They guided full year up by 12 cents, which suggests The next quarter is going to be sort of, I don't know, pedestrian at best at a big valuation. Given the run, I mean, it makes sense that the stock is lower. I think it should be lower than it is now, given the valuation. So it was a fine quarter. Guy, it's not great. I think the stock trades down. There's a lot more fast money to come. Here's what's coming up next. Is the punishment over? How the asset cap on Wells Fargo could be lifted? And what's changed at the bank since their fake account scandal?
25:07Plus, hefty losses, not enough to tip the scales. The latest data out of Amgen's obesity drug trial. And why Wall Street was expecting even more outsized results. You're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.
25:34Welcome back to Fast Money, the Dow and S &P 500, closing at fresh record highs. The S &P also notching its seventh straight day of gains. And the Nasdaq also higher up six tenths of a percent. Shares of Procter & Gamble up today, now on a 10-day winning streak, its longest rally in 17 years. And some more after hours action, Workday, Urban Outfitters, Autodesk, Amborella posting earnings and revenues that beat expectations. Amborella with a big move higher after upping revenue guidance for the fourth quarter, and shares of HP lower after reporting earnings in line with estimates. And do not miss the CEO of HP on Mad Money.
26:06That's 6 p.m. Eastern right after Fast Money here on CNBC. Take a look at Rivian receiving conditional approval for a loan of up to$6.6 billion from the Department of Energy to build its production facility in Georgia. The EV maker pausing development of the plant back in March due to concerns about its capital position. And Wells Fargo may be nearing an end to its asset cap punishment. The constraint put on the bank back in 2018 after its fake account scandal. But now the bank is reportedly in the last stages of passing regulatory tests to lift that growth constraint. According to this report, the punishment could be removed as early as the first half of next year.
26:42Coming up, heavy losses, but not enough to carry the weight of the stock. How Amgen's latest obesity drug data isn't meeting Wall Street expectations and what it means for the entire weight loss drug space. Fast Money is back in tune.
27:02Welcome back to Fast Money. Amgen closing nearly 5 % lower, well off its worst levels, but still the biggest drag on the Dow. The company out with phase two data on experimental obesity drug Meritide, showing patients lost up to 20 % of their body weight on average at 52 weeks without plateauing. But the results seemingly not enough for the street. CNBC's Angelica Peebles joins us now with more. Angelica. Yeah, Melissa, the street was looking for 25%. So that 20 % reduction, disappointing right there out of the gate. But the bigger concern today was the side effects. Amgen saying that 11 percent of people dropped out of the trial because of any adverse events and 8 percent dropping out because of GI issues like nausea and vomiting.
27:41Now, of course, these side effects are not new for GLP-1s, but Amgen described pretty high rates and they didn't give a detailed breakdown of the severity, just generally describing them as mostly mild. Now, they did say that the side effects were typically after the first shot and they're planning on starting with a lower dose in the phase three. And on that phase three, Amgen not saying whether they'll go with a once a month dose or once every other month. So stay tuned there. And also today, the Biden administration proposing Medicare and Medicaid cover obesity medications. That would give about seven million Americans access to these drugs.
28:14The current administration, though, they won't be able to implement that policy before January. So it'll be up to the Trump team to decide what they want to do with it. Melissa. All right, Angelica, thank you. Angelica Peebles. Let's get more with Piper Sandler, senior research analyst Chris Raymond. He reiterated his overweight rating on Amgen after the results crossed. Chris, great to have you with us. Great to be here. Thanks for having me. You know, there was an assumption after this data came out that, you know, it won't get better in phase three. And yet, as Angelica had pointed out, there wasn't plateauing at the end of 72 weeks, which indicates that perhaps there could be more weight loss to come, which could actually then surpass her Zapatide.
28:51So what is Wall Street not sort of taking into consideration in evaluating the results so far? Right. Well, yeah, I think you hit the nail on the head. The data showed clearly that the drug's efficacy effect was not plateauing at 52 weeks. And you've got to understand we're comparing 52 weeks to trisepatide, which had its data, and essentially spot on in terms of weight loss, 20 percent for both. So trisepatides was at 72 weeks. And if you look at the curves that Amtron presented today, clearly it's headed even higher. So I think, you know, from my perspective, just hold on a few weeks here. We'll get longer term data.
29:34And I think the superiority will be a lot clearer. Getting people over the hump, though, in terms of not dropping out because of the severe side effects so early on, that could be an issue. Do you think that resolves in phase three? Do you think it resolves if you start people off at a lower dose? Yeah, TBD. The company, rightly, is being a little bit cagey on their phase three design. It's a very competitive market. They did present some interesting data with patients starting at a much lower dose. And they didn't give us the numbers, but said it was much lower than what they presented. but a little perspective.
30:09We're talking essentially a 6.7 discontinuation rate for terzepatide versus the 11 % overall number that we saw with maritide. So we're kind of in the same ballpark here in terms of discontinuation rates. GI related, there are a couple percentage points higher for maritide. But the tradeoff, again, you've got much faster weight loss, And you also have, you know, essentially a game changer in terms of being dosed once monthly versus once weekly. Chris, we're talking about a company, and I'm leading the witness, 13, 14 billion dollar drugs, probably trades at, I don't know, 14 times next year's numbers, coming off what I thought was a great quarter in late October.
30:58That's probably priced in this news on the back of the sell off the stock has seen over the last couple of months. So at a certain level, you just have to sort of close your eye and buy this thing, I think. Well, yeah. Or you could keep your eyes open, you know, and look at the potential value of this drug. You know, we're talking, you know, a segment that I don't think there's really much debate. This is ultimately going to be approaching$100 billion of revenue, you know, the obesity GOP market. So it doesn't take a ton of share to have a real needle mover, especially for a company like Amgen.
31:31And so I do think this is, you know, not just an overreaction, but, you know, a misplaced reaction. All right. Chris, great to have you with us. Thanks for your perspective. Chris Raymond of Piper and a quick programming note here. Once you've recovered from your Turkey Day binge, don't say that. We're bringing you special coverage of the weight loss industry. Fast Money's Obesity Week starts off next week, Monday, December 2nd. Bringing together top CEOs and thought leaders in the industry. That's right here at 5 p.m. Eastern every day next week. It's not very nice to do obesity week after Thanksgiving.
32:02Come on. I mean, people go back for an extra plate of stuffing. I mean, it's, you know, it's what you do. It just happened to be that we picked next week, okay? It really has nothing to do with Thanksgiving. Does Tim have a big role in obesity week? Anyway, the chart is not great with Novo, it seems to me. The performance has not been good. So I'm actually intrigued by Amgen in a way, because when you see a big gap down after a downdraft, If the stock was down about 25 percent at today's low off the mid-year high, it's intriguing when you get a heavy volume gap down following the decline. The last time that happened for Amgen was a short term low on August 7th.
32:39Of course, the market was bottoming, too. But it does tend to be climactic. Right. So if folks are looking to exit their longs, at a very minimum, they should probably wait. Right. The other differentiating factor between this drug and the others is that it's once a month. So imagine once a month as opposed to once a week. Look, I'll leave it to the pharma experts on GLP especially. But, you know, there are other elements of this analysis that say you're going to have higher weight loss in part two. And this is fine. And that this is a sell the news events. It sounds like this is a group that would be buying this weakness.
33:10I would be right there. That bounce off of 260 is a reset back to one year loves. Coming up more after hours action this time. Nordstrom shares on the move after reporting results and numbers from that quarter next. Plus the morning retail earnings that had Dix, Abercrombie, Kohl's and Best Buy in the red. at the details and the trend, keeping that space in the clearance section when Fast Money returns.
33:40Welcome back to Fast Money. We've got an earnings alert on Nordstrom, the department store stock at after-hours lows following its latest results. A call is underway. Courtney Reagan's got the latest. Court. Hi, Melissa. Yeah, so much going on here today, but Nordstrom's earnings here after the bell with earnings revenue, comparable sales actually coming in all better than expected. Comparable sales up 4 percent. That was much stronger than the 0.7 percent growth that was consensus. Now Nordstrom only taking up its bottom line of the sales glide and slightly adding sort of to this general conservatism from a chorus of retailers about the holiday quarter, regardless of how strong or not the third quarter might have been.
34:12And while Nordstrom saw strength in apparel and shoes, off-mall department store Kohl's reported weakness for both of those categories. Now, Kohl's put up its 10th straight quarter of declining comparable sales and announcing a new CEO. Clearly a lot of work to do. Abercrombie Dick's Sporting Goods, again, both outperforming expectations with continuing sales growth and guidance raise streaks. Meantime, Best Buy logs its 11th straight quarter of comp declines. CEO Corey Berry pointing largely to external factors like macro uncertainty, distraction in the run up to the election, customers waiting for deals as basically what was to blame for the results.
34:46Now, She did say comp sales were up 5 % in the first three weeks of November, but that's just about 20 % of the quarter. Back over to you guys. It feels like Kohl's, Courtney, has had a lot of CEOs in a very short amount of time, and that this quarter was really the result of just sort of miscalculation when it came to private label and amping up sort of the brand name items in the store. Yeah, absolutely. I know that the CEO comment is an interesting one. When we got the news yesterday, I sort of went back to the timeline myself. I think it's the third CEO since 2018. 2018. So it was Michelle Goss.
35:16And then she left kind of surprisingly. Tom Kingsbury took over and now Ashley Buchanan is going to take over over him. But, yes, I mean, clearly, I don't think the Kohl's story has anything to do really with the consumer. I don't think it's talking about weakness of the consumer. And I don't even necessarily you can even point to the categories because Nordstrom had strength in the exact categories that were weak at Kohl's. You may argue they're different customers, but Walmart also saw some strength in some of those general merchandise categories for the second quarter in a row in a different customer, I would argue, than typically is that Nordstrom.
35:43So I think to your point, I think it was a lot of, you know, missteps by Kohl's operations. I mean, comparable sales down 9.3 percent. That is significant and significantly worse than the street had expected. Yeah. Court, thanks. Thanks. Courtney Reagan. Where do you want to shop? Nordstrom. Oh, look at you. Nordstrom's. I'll shop there. I think one of the reasons it sold off, it was a$22 stock a week ago, traded up to$25. That's a big move. But look at the quarter. Four percent comps against what the street was looking for is great. Their margins were better. Merchandise only up 5.9 % year over year is not a disaster.
36:17I think it was the full year guide that was in line. They're sort of sandbagging. So I think you buy Nordstrom's here. I think their numbers are solid. I think there's a floor under the stock with the take private bid. I think there's a real surprise. I think RAC is RAC proud. I mean, it continues to be the place to go. You know, I am interested in the chart. It looks like a long-term turnaround phase. So pullbacks could be entries in that kind of setup. And if you look at XRT, the retail ETF, we do have some, you know, sort of signs that it's breaking out from this big range. So I'm encouraged by the action.
36:50It's a little bit early. We'll see. Yeah. Speaking of rack, I want to go to Dick's here because I just thought that quarter was really interesting. The stock gapped up and it looked like it was actually going to test the high end of that range over the last five or six months ago. But some of the commentary that you heard from a Dick's or a Best Buy doesn't leave you feeling that great about the retail environment. I mean, it seems to be very promotional. We know that a lot of this started, you know, about a month ago or so. So to me, I just think this is a really hard time for these retailers to report and kind of give their guidance.
37:19But again, it doesn't feel particularly strong. Coming up, small caps driving the action. How the Russell 2000's record gains could fuel a resurgence in the IPO market. And where our next guest sees the best opportunities. More Fast Money in two.
37:42Welcome back to Fast Money. Small caps having a banner month. The Russell up almost 10 percent in the last four weeks. The index now less than 1 percent off its record high hit during yesterday's trading session. And our next guest thinks the Russell's record gains could help revive the IPO market. Seth Rubin is Stiefel's head of Global Equity Capital Markets. Great to have you with us. Great to be here. Thanks. Where are you expecting the newest companies to be minted? Which sectors? Yeah, well, I do think, by the way, your comment on the small cap rally is hugely important to the market because that's really where the heart of the market is, the heart of the U.S.
38:15new issue market and the IPO market. Look, I think we're going to see a real pickup inactivity across the board. I'm most focused right now on tech and fintech because you guys know we've been averaging, had been averaging about 40 tech IPOs a year for the last 10 years, and there's been fewer than 40 over the past three years combined, right? So there's just a huge backlog of really high-quality companies. Big we're excited about. I think it could be the biggest beneficiary of deregulation in terms of what's going on in the broader market. And then in healthcare. And we talk about the up and downs on a day-to-day basis in healthcare, and particularly in biotech.
38:48But innovation and AI-driven drug discovery is really accelerating companies to market. And frankly, public markets are the best place for biotech companies to be able to continue to raise capital to fund trials. So I'm excited across the board. Ruben, you just mentioned 40 IPOs in the tech market over the last three years. What do you think private companies have learned since the 2021 period where we saw a lot of companies go public via SPAC that probably shouldn't be in the public markets? You know, I think most importantly, they've learned that they have to perform as public companies. Right.
39:18We it might be a cheesy line, but we say it all the time when we price IPOs. We say, welcome to the starting line. Right. And that's where it begins. So I think companies are being a lot more thoughtful and a lot more conservative about the type of guidance they put out, making sure they can beat and raise, and really having great visibility into the next 6, 8, 12 quarters so that they know they can get out there and they can perform as public companies. I think this next wave is not going to be about top-ticking valuation on the way in. It's going to be about raising enough capital to really grow the business and then be able to perform for a number of years and get investors in at the right prices and give them an opportunity to make money along the way.
39:55So is the trade banks, Seth, off all of this? I mean, that's the bottom line, right? I'm sorry? Is the trade off of this belief that there's going to be a wave of IPOs, is the trade banks? Yeah, look, I think you know our views and we cover the bank sector and we're hugely bullish on banks and regional banks and the brokerages that are involved in the activity of the IPO market and the M &A market. So, look, I can only speak to our pipeline and what I see there on the street, but I think we're all gearing up for a really active 25 and 26. All right. Seth, thank you very much for your time. Seth Rubin, Stiefel.
40:29Thanks, Brett. First of all, the great Rubin of all time is Rubin Kincaid, the Bartridge family. Quick apology. I don't know why. I had Rubin in the brain, but Seth. That's fine. Number two, the NASDAQ is the place to go. I think it was just initiated outperforming William Blair. I mean, they stand to win, made a new all-time high today. It's NDAQ, Melms. Small cap index. How does it look? You know, it's new highs, essentially. So what we're watching is resistance around 2360 for the Russell 2000 index. That's a key level. If it can hold above there, it confirms a breakout. We're not buyers right here.
41:04It's pretty overstretched short term, in our opinion. But it could be a major breakout. Yeah. Do you think there's an IPO pipeline to be had next year? 100%. I mean, I think there was like three or five tech IPOs last year. There's a huge pent up demand, just as Seth just told us. Well, this all tells me equities are going higher. I mean, there's so much liquidity out there. There are a lot of private equities getting exits teed up. The M &A market is going. This is part of the backdrop for equities that I think. And this is what people are expecting. It's going to happen. By the way, calling Seth Rubin Rubin is really not too bad.
41:39I remember when the CEO of Bob Evans was on. Yeah, I called him Mr. Evans. That was completely off base. Or that's Tim Apple. That didn't go so well. Tim Apple. Charles Schultz. There's so many others. Or you've been called Michelle like 100 times. 100 times, right? Whatever. Charles Schultz. Of next final trades.
42:08Time for the final trade, Tim Seymour. That MGen opportunity doesn't have to be tomorrow, but this is a company I think both on valuation. Guy talked about what's overall in the pipeline. I think this data was something new. Katie Stockton, a fair lead strategies. I think everyone should check out Genesco. The ticker is GCO. Got a great face breakout. What do they do? I'm just kidding. Great to have you, Katie. I see what you see in the Russell, the IWM, but I wouldn't be chasing it here. It looks like an epic what guy? Double top. We were just saying before, during the break, that Tim and I were saying that Mel wouldn't have liked this in college.
42:45In college, not much. I don't know. And then you said, we don't like you now. So, I mean, it's just that we have feelings. Is that true, Tim? I think they pick on the ones they... I agree with that. I agree. J.W. Yorkshems, I think the market's picking on them now, unjustifiably now. All right. Thanks for watching Fast. See you back here tomorrow at 5 for more Fast. Pump day, gobble, gobble. Thanksgiving Eve. Oh, boy. Mad Money with Jim Kramer starts right now.
43:12All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.
43:47To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.
From the publisher
Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
